James Weatherall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James Weatherall has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Curth
Department of Applied Mathematics & Theoretical Physics University of Cambridge Cambridge UK
1 shared publication - Eoin F. McKinney
Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
1 shared publication - Jorge Sergio Reis-Filho
Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY USA
1 shared publication - Mihaela van der Schaar
University of Cambridge
1 shared publication - Richard J. A. Goodwin
AstraZeneca (United Kingdom) 1 Predictive AI & Data, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D Cambridge, United Kingdom
1 shared publication - Richard Wilson Peck
Department of Pharmacology & Therapeutics University of Liverpool Liverpool UK
1 shared publication
Latest Publications
- 18 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF5
Enabling AI to Drive Innovation and Precision across Oncology R&D
Summary: The use of integrated large-scale, multidomain datasets with artificial intelligence (AI) is now essential in drug discovery and development. Organizations that strategically invest in robust data infrastructure and fit-for-purpose AI solutions will accelerate the delivery of precision oncology therapeutics globally.
- 18 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF5
Enabling AI to Drive Innovation and Precision across Oncology R&D
Summary: The use of integrated large-scale, multidomain datasets with artificial intelligence (AI) is now essential in drug discovery and development. Organizations that strategically invest in robust data infrastructure and fit-for-purpose AI solutions will accelerate the delivery of precision oncology therapeutics globally.
- Top Cited PapersOpen Access
- 12 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (4) , 710-719
Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities
The use of data from randomized clinical trials to justify treatment decisions for real‐world patients is the current state of the art. It relies on the assumption that average treatment effects from the trial can be extrapolated to patients with personal and/or disease characteristics different from those treated in the trial. Yet, because of heterogeneity of treatment effects between patients and between the trial population and real‐world patients, this assumption may not be correct for many patients. Using machine learning to estimate the expected conditional average treatment effect (CATE) in individual patients from observational data offers the potential for more accurate estimation of the expected treatment effects in each patient based on their observed characteristics. In this review, we discuss some of the challenges and opportunities for machine learning to estimate CATE, including ensuring identification assumptions are met, managing covariate shift, and learning without access to the true label of interest. We also discuss the potential applications as well as future work and collaborations needed to further improve identification and utilization of CATE estimates to increase patient benefit.
- 12 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (4) , 710-719
Top Cited PapersOpen AccessUsing Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities
The use of data from randomized clinical trials to justify treatment decisions for real‐world patients is the current state of the art. It relies on the assumption that average treatment effects from the trial can be extrapolated to patients with personal and/or disease characteristics different from those treated in the trial. Yet, because of heterogeneity of treatment effects between patients and between the trial population and real‐world patients, this assumption may not be correct for many patients. Using machine learning to estimate the expected conditional average treatment effect (CATE) in individual patients from observational data offers the potential for more accurate estimation of the expected treatment effects in each patient based on their observed characteristics. In this review, we discuss some of the challenges and opportunities for machine learning to estimate CATE, including ensuring identification assumptions are met, managing covariate shift, and learning without access to the true label of interest. We also discuss the potential applications as well as future work and collaborations needed to further improve identification and utilization of CATE estimates to increase patient benefit.